First, 68% of all injectable device registration requests for obesity and diabetes treatment filed with Anvisa are for synthetic drugs a category that has grown rapidly since the development of laboratory-synthesized versions of the GLP-1 hormone in 2022
Chronic semaglutide alters ingestive behavior without impairing taste function in mice
Clinical trials and real-world studies have demonstrated impressive results: Liraglutide (Saxenda) : Studies have shown that individuals using liraglutide for weight management can achieve an average weight loss of 5-10% of their body weight over a 56-week period
Tirzepatide is administered as a subcutaneous injection with dosage guidance adjusting to the patients needs
Understanding your genetic predispositions, combined with clinical monitoring and provider guidance, allows for truly personalized GLP-1 management strategies
Juliet, TN Putting Control in Your Hands Lets dive deeper into the science behind emotional eating, because finding comfort in food is what makes intuitive eating so challenging
